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Introduction {#sec1}
============

During epithelial to mesenchymal transition (EMT), epithelial cells change phenotype, lose cell polarity, and become migratory and proliferative. Pathological EMT can result in cell proliferation, invasion, and metaplasia ([@bib13]). In the human retina, healthy retinal pigment epithelium (RPE) consists of a single, non-proliferative neuroepithelial cell layer that supports neural retinal function. RPE cells form a polarized monolayer with tight junctions, contributing to the blood-retina barrier. If triggered, RPE cells undergo EMT, delaminate from the epithelial layer, proliferate, and acquire mesenchymal characteristics. These mesenchymal-like RPE can contribute to epiretinal membrane (ERM) formation in macular pucker ([@bib38]) or more aggressive proliferative vitreoretinopathy (PVR), characterized by contractile ERMs that can pull and damage the retina ([@bib18], [@bib41]). The molecular basis of pathological RPE EMT, including changes in gene expression and regulation, remain poorly understood.

Retinal tears due to vitreoretinal traction and retinal detachment are common preceding PVR ([@bib9], [@bib19]). RPE cells become dislodged from their niche, are released into the vitreous through the retinal tears and become exposed to inflammatory cytokines that stimulate migration, proliferation, and PVR. Many of these cytokines, including transforming growth factor β (TGF-β) and tumor necrosis factor alpha (TNF-α), are made by the RPE cells themselves or other cells in the pathological tissue, such as macrophages ([@bib19], [@bib25], [@bib27]). TGF-β is increased in the vitreous of patients with PVR, correlated with PVR severity ([@bib14]). TNF-α is also increased in the vitreous of patients with PVR and macular pucker ([@bib16]). Studies of patient-derived PVR membranes reveal activation of both TGF-β and TNF-α signaling pathways ([@bib1], [@bib32]) and both gene loci have SNP risk associations with PVR ([@bib31], [@bib35]). TNF-α has been found to activate TGF-β expression ([@bib40]), and therefore the combinatorial effects warrant further study. Receptors for TGF-β and TNF-α are expressed on human native RPE cells ([@bib39]) and several studies document human RPE responses to these factors.

We found that TGF-β1 and TNF-α synergistically activate an EMT program in adult human RPE stem cell (RPESC)-RPE, producing fibroblastic, contractile membranes *in vitro* resembling ERMs found in macular pucker and PVR. To characterize the process underlying this cellular transition, we comprehensively mapped the associated epigenetic and transcriptional changes. The most prominent epigenomic change accompanying RPE EMT was a gain of active chromatin marks at many putative enhancer elements. Correlating the epigenomic and transcriptomic data of TNT-treated RPE, we identified the landscape of gene regulation accompanying EMT, identifying several transcription factors (TFs) as candidate regulators of this process.

Previously, we reported that the TGF-β pathway and inflammatory processes are significantly inhibited in human induced pluripotent stem cell-derived RPE treated with the vitamin B3 derivative nicotinamide (NAM) ([@bib33]). Here, we demonstrate that NAM treatment of adult RPESC-RPE enhances the epithelial phenotype, prevents EMT, preserves RPE cell identity, and prevents the contractile behavior stimulated by combined TGF-β1 and TNF-α treatment ([@bib36]). Understanding the molecular changes accompanying RPE EMT and the impact of NAM has the potential to benefit patients with ERMs that contribute to vision loss.

Results {#sec2}
=======

Combined TGF-β1 and TNF-α Treatment Induces Adult Human RPESC-RPE to Undergo EMT {#sec2.1}
--------------------------------------------------------------------------------

RPESCs were isolated and expanded from adult human cadaver globes, then differentiated into quiescent, polarized cobblestone monolayers ([@bib2], [@bib8]) ([Figure 1](#fig1){ref-type="fig"}A). Adult RPESC-RPE cell cultures from three donors were treated with TGF-β1 alone, TNF-α alone, or their combination TGF-β1 + TNF-α (TNT), for 5 days. Treatment with either factor singly caused the RPE cells to transition from a cobblestone to a fibroblastic monolayer, while with the combined TNT treatment RPE cells acquired a more advanced mesenchymal phenotype and formed 3D aggregates ([Figure 1](#fig1){ref-type="fig"}B). Time-lapse movies capturing the dynamic changes occurring upon TNT treatment show increased motility and apparent contractile behavior with 3D membrane-like formation ([Video S1](#mmc6){ref-type="supplementary-material"}).Figure 1TGF-β1 + TNF-α Co-treatment (TNT) of RPESC-RPE Cells Induces EMT and Formation of *In Vitro* Membranes Similar to ERMs(A) Schematic of RPE isolation and *in vitro* ERM model generation.(B) Phase images showing RPE cells in control conditions (cobblestone morphology) or 5 days after treatment with 10 ng/mL of TGF-β1, TNF-α, or both TGF-β1 + TNF-α (TNT).(C) Time course (0, 1, 3, and 5 days) of *SNAI1*, *SNAI2*, and *TWIST1* expression in control RPESC-RPE cells (vehicle treated) and with 10 ng/mL of TGF-β1, TNF-α, or both (TNT), n = 3 biological replicates.(D) Immunofluorescence images of RPE cultures stained with anti-SNAI1 antibody show upregulation in TNT conditions.(E) Fundus image of a patient with ERM (indicated by dotted line).(F) RNA isolated from patient ERMs compared with *in vitro* RPE in control and TNT conditions assessed by qPCR for expression of RPE and EMT genes. n = 4 biological replicates. Scale bars, 50 μm. ^∗∗^p ≤ 0.01.

Video S1. Video of RPE Treated with TGF-β1 and TNF-α

TNT treatment led to synergistic upregulation of the EMT master TFs *SNAI1*, *SNAI2*, and *TWIST1* ([Figure 1](#fig1){ref-type="fig"}C). *SNAI1* expression increased 112.23 ± 27.91 (fold over control), p \< 0.01 (n = 3), after TNT treatment but only 7.89- ± 2.21-fold, p \< 0.05 (n = 3) after TGF-β1 alone and was similar to control after TNF-α alone. *SNAI2* expression increased 36.08- ± 6.31-fold, p \< 0.01 (n = 3) upon TNT treatment, while TGF-β1 alone and TNF-α alone had little effect. *TWIST1* expression increased 11.26- ± 1.05-fold, p \< 0.01 (n = 3) in TNT conditions compared with control, while treatment with TGF-β1 alone increased *TWIST1* expression by 6.36- ± 1.91-fold, p \< 0.05 (n = 3) and TNF-α alone had negligible effect. The upregulation of nuclear localized SNAI1 protein in TNT conditions was confirmed by immunocytochemistry ([Figure 1](#fig1){ref-type="fig"}D).

We compared expression of genes characteristic of RPE (*MITF* and *BEST1*) and EMT (*SNAI1*) in 5-day TNT-treated versus vehicle-treated (control) RPE cells isolated from four different donors versus ERMs surgically removed from four different patients ([Figures 1](#fig1){ref-type="fig"}E and 1F). Patient-dissected ERMs expressed *MITF* at significantly lower levels: 0.21 ± 0.79, p \< 0.01 (n = 4) than control RPE (normalized to 1 for each sample), as did TNT-treated RPE 0.055 ± 0.023, p \< 0.01 (n = 4). *BEST1* expression in patient-dissected membranes varied widely 19.48 ± 14.47, p \> 0.05 (n = 4), and was not significantly different from control RPE or TNT-treated RPE 2.63 ± 2.63, p \> 0.05 (n = 4). *SNAI1* expression was significantly increased in patient-dissected membranes 12.5 ± 2.13, p \< 0.01 (n = 4), compared with control RPE, consistent with the high level of *SNAI1* expression in TNT-treated RPE (22.51 ± 1.46, p \< 0.01; n = 4) and with prievious findings in PVR tissue. Hence, TNT-treated RPE and patient-dissected ERMs have related morphological and gene expression changes, corroborating our previous studies ([@bib36]).

TNT Induces Dynamic Changes in Enhancer Epigenetic Status {#sec2.2}
---------------------------------------------------------

We performed chromatin immunoprecipitation (ChIP) for the histone marks H3K27ac, H3K4me3, and H3K4me1 and identified enrichments across the genome; there was good correlation between replicates (e.g., [Figure S1](#mmc1){ref-type="supplementary-material"}). When signal enrichments from control vehicle-treated cobblestone versus TNT-treated EMT RPE cells were compared, a major reorganization of H3K27ac and, to a lesser degree, H3K4me1 patterns upon EMT induction was apparent; interestingly, unlike many cell fate transitions that we have previously studied ([@bib4]) this EMT-associated reorganization is highly asymmetric with many more sites gaining H3K27ac (red) than losing (blue) or remaining unchanged (orange) ([Figures 2](#fig2){ref-type="fig"}A and 2B). This indicates that more regulatory elements become activated than are decommissioned upon TNT treatment (approximately 11,000 versus 4,000 at false discovery rate \[FDR\] \< 0.1).Figure 2TGF-β1 + TNF-α (TNT) Co-treatment of RPESC-RPE Cells Induces Global Epigenetic Changes at Enhancer Elements(A) TNT co-treatment induced changes in *H3K27* acetylation: abscissa---normalized read density of *H3K27ac* ChIP-seq at chromatin features (putative enhancers and promoters) in cobblestone RPE cells; ordinate---normalized read density of *H3K27ac* ChIP-seq in TNT-treated RPE cells. Regions in red have significantly upregulated ChIP signal upon TNT treatment (FDR \< 0.01), in blue downregulated (FDR \< 0.01), and in orange no change (FDR \< 0.1).(B) Changes in the H3K4me1 ChIP signal are correlated with *H3K27ac* changes, regions color coded according to the *H3K27ac* classes defined in (A).(C) TGF-β1 + TNF-α treatment results in relatively few changes in promoter signatures. Negative values indicate a promoter-like chromatin signature at interrogated sites. Color coding as in previous panels.(D) Most changes in *H3K27* acetylation occur at sites distal from annotated transcription start sites. Plotted is the absolute distance to the closest annotated TSS versus the log2 fold change in the *H3K27ac* ChIP signal: genes associated with distal elements with upregulated *H3K27ac* (red), downregulated *H3K27ac* (blue), or unchanged (orange). The differences are significant with p values indicated (Mann-Whitney-Wilcoxon test). n = 2 biological replicates.

To investigate whether these changes correspond to epigenomic reorganization at enhancers or promoters, we analyzed the H3K4me1/H3K4me3 ratios and observed that regions that gain H3K27ac (e.g., identified as red in [Figure 2](#fig2){ref-type="fig"}A), tend to have a high H3K4me1/H3K4me3 ratio, suggestive of enhancer identity, whereas the regions that lose H3K27ac (blue) or remain unchanged (orange) are represented among both high and low H3K4me1/H3K4me3 ratio regions, indicating that they may harbor either promoter or enhancer activity ([Figure 2](#fig2){ref-type="fig"}C). Consistent with the notion that RPE EMT is associated with widespread enhancer activation, most regions with changes in H3K27ac were located more than 10 kb away from the nearest transcription start site ([Figure 2](#fig2){ref-type="fig"}D), as would be expected with long-range elements, such as enhancers.

Functional annotation of these dynamically changing, putative active enhancer regions by GREAT analysis revealed association of TNT-induced enhancers with arteriosclerosis, wound healing, growth factor activity, and cell growth and proliferation ([Figure S2](#mmc1){ref-type="supplementary-material"}A), whereas regulatory regions that were downregulated by the TNT treatment were linked to retinal epithelium, RPE, visual perception, and retinal degeneration categories ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Regulatory regions found unchanged between control cobblestone RPE and TNT-treated RPE included both injury-related and neural development terms ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Altogether, we found that TNT treatment of RPE is associated with massive reorganization of epigenomic patterns, especially with the induction of thousands of new putative enhancer elements.

Transcriptional Changes in RPE after TNT Treatment {#sec2.3}
--------------------------------------------------

Observed widespread epigenomic changes prompted us to investigate changes in gene expression that accompany TNT treatment of RPE. Using RNA from the same samples used in the ChIP sequencing (ChIP-seq) analysis, we performed RNA sequencing (RNA-seq) to examine the changes in transcription occurring due to TNT treatment ([Table S1](#mmc2){ref-type="supplementary-material"}A). To target more precisely the associated gene expression changes, we used EdgeR and DESeq packages to compare RNA-seq data from the four conditions: cobblestone RPE treated with vehicle (control) to TNF-α alone ([Table S1](#mmc2){ref-type="supplementary-material"}B), TGF-β alone ([Table S1](#mmc2){ref-type="supplementary-material"}C), or both (TNT) ([Table S1](#mmc2){ref-type="supplementary-material"}D). Compared with cobblestone RPE, 567 and 18 genes significantly changed after 5 days of treatment with TNF-α or TGF-β alone, respectively, while a much larger number, 2,839 genes, changed significantly after TNT treatment, consistent with the synergistic effect of the two pathways ([Table S1](#mmc2){ref-type="supplementary-material"}D) (FDR = 0.01). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the genes upregulated in TNT indicates focal adhesion, ECM-receptor interaction, cytokine responses, and regulation of the actin cytoskeleton, fitting with observed changes in cell morphology, adhesion, and response to exogenous factors, while downregulated genes are primarily in metabolic pathways ([Figures 3](#fig3){ref-type="fig"}A and 3B; [Tables S2](#mmc3){ref-type="supplementary-material"}A and S2B). Gene ontology enrichment analysis with the cateGOizer webtool ([@bib24]) gives a similar picture, with the fraction of terms associated with development, morphogenesis, differentiation, and cell signaling forming a larger fraction of the enriched terms in the TNT-treated compared with control RPE cells ([Figures 3](#fig3){ref-type="fig"}C and 3D; [Tables S3](#mmc4){ref-type="supplementary-material"}A--S3D). We explored further the expression of TGF-β and TNF-α receptors, confirming their expression in cobblestone RPESC-RPE and examining how the expression changed upon cytokine treatment by STRING analysis and qPCR ([Figure S3](#mmc1){ref-type="supplementary-material"}). Interestingly, TGFBR2 increases after TNT treatment, while TGFBR3 decreases.Figure 3RNA-Seq of RPE Undergoing TNT-Stimulated EMT Correlated with Epigenomic Changes(A and B) KEGG pathway enrichment analysis using the genes significantly upregulated (A) or downregulated (B) after TNT treatment(C and D) Gene ontology category analysis with goseq in combination with cateGOizer to classify and summarize the enrichment analysis revealed pathways enriched TNT-induced EMT RPE (C) and pathways enriched in cobblestone RPE (D). N = 2 biological replicates.

To examine the relationship between genes increased in TNT-treated RPE and other tissues undergoing EMT, we interrogated the dbEMT resource (<http://dbemt.bioinfo-minzhao.org/>), a manually curated database of genes experimentally verified to play a role in EMT across a variety of cancers and tissues ([@bib44]). Of the 344 genes in the dbEMT resource, 63 genes, approximately 20%, were also upregulated in RPE after TNT treatment, which is a strong enrichment (Fisher's exact test, p \< 0.001). Overall, the results of expression data analyses are consistent with changes in cell function and activity associated with the dramatic phenotypic changes that RPE cells undergo upon TNT treatment, and reveal both similarities with gene expression changes associated with EMT in other tissues and those more unique to RPE EMT.

Integrating Transcriptional Changes Identifies RPE EMT-Related Genes {#sec2.4}
--------------------------------------------------------------------

We then sought to understand the relationship between the epigenetic reorganization and changes in gene expression upon TNT treatment. We identified 12,516 unique genes closest to the 40,949 significantly changing regions based on H3K27ac marks ([Table S1](#mmc2){ref-type="supplementary-material"}A), including 10,264 unique genes closest to the putative enhancer marks ([Figure 4](#fig4){ref-type="fig"}A). Of those genes with associated promoter or enhancer peaks, 2,293 genes also showed changes in expression in the RNA-seq analysis ([Figure 4](#fig4){ref-type="fig"}A), which represents ∼80% of the genes identified as changing. Broadly, regulatory elements that lose H3K27ac upon TNT treatment are associated with downregulated genes, and those that gain H3K27ac are associated with upregulated genes ([Figure S4](#mmc1){ref-type="supplementary-material"}).Figure 4Integration of Transcriptional Changes and Epigenetic Changes during TNT-Induced EMT(A) Scatterplot of expression changes after TNT treatment with selected transcription factors highlighted.(B) Venn diagram showing the intersection between the differentially expressed genes and genes with either enhancer only or enhancer and promoter peaks.(C) Venn diagrams of genes with significantly changing peaks in the cobblestone RPE (yellow) or with TNT-induced EMT RPE (green) overlapping with genes exhibiting increased (red) or decreased (blue) expression during EMT.(D and E) Homer motif analysis of the subset of peaks and genes identified in (C) by ^∗^ (D) or \$ (E) identified key TFs potentially regulating the genes in each subset. Directed graphs based on the motif analysis were constructed and the minimum connecting dominating sets were identified. Shown are the subgraphs of the TFs for the RPE network (D) and the TNT network (E). Complete graphs and the motif analysis can be found at <http://neuralsci.org/computing>.

In all, 2,997 and 6,932 genes were associated with enhancer peaks of different intensities in the RPE cobblestone and TNT conditions, respectively ([Figure 4](#fig4){ref-type="fig"}B). Of the genes associated with more intense enhancer peaks in RPE cobblestone cells, 768 also changed expression after TNT treatment, with most decreasing. Of the genes associated with more intense enhancer peaks after TNT treatment, 1,386 also changed expression: downregulated genes were again the majority, but the upregulated genes were more prominent compared with upregulated genes associated with RPE cobblestone peaks (625 \[45%\] versus 153 \[20%\] genes) ([Figure 4](#fig4){ref-type="fig"}C).

Although most changes occurred at distal enhancers, changes in epigenetic marks around the promoters of some significantly changing genes were also apparent. Of the 2,839 genes changing after TNT treatment, 1,997 also showed significant changes in the epigenetic marks near their promoters. For example, *INHBA*, *COl1A1*, and *TGFβ1* molecules positively associated with EMT, showed upregulation of H3K4me1, and associated H3K27ac marks in promoter regions upon TNT treatment, while characteristic RPE genes, including *BEST1* and *RPE65*, showed reduction in these active promoter marks, changes also reflected in respective transcription levels ([Figure S5](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc2){ref-type="supplementary-material"}A). Together this analysis demonstrates a strong correspondence between the dynamic epigenetic and transcriptional changes we identified during TNT-induced EMT.

Transcription Factor Changes Associated with RPE EMT {#sec2.5}
----------------------------------------------------

Considering the importance of TFs in binding to regulatory regions and executing gene expression changes, we evaluated which TFs may be involved in RPE EMT. Of the 2,839 genes that changed expression significantly between control cobblestone and TNT conditions, 424 were identified as likely TFs (GO:0006355, "regulation of transcription, DNA-templated") ([Table S4](#mmc){ref-type="supplementary-material"}A). These include known master regulators of EMT, such as *SNAI1* and *SOX4* ([@bib42]), and TFs more recently associated with EMT, such as *LMCD1* ([@bib6]), and several not previously associated, such as *FOXS1 (*[Figure 4](#fig4){ref-type="fig"}A). Examination of histone marks in several of these TFs revealed expected changes reflecting their increased level of transcription, including increased H3K27ac at promoter regions ([Table S1](#mmc2){ref-type="supplementary-material"}A). Conversely, RPE-associated TFs, such as *MITF* and *OTX2* showed lower expression levels in TNT versus RPE control conditions and overall reduced level of histone marks associated with transcriptional activity after TNT treatment ([Table S1](#mmc2){ref-type="supplementary-material"}A).

To better understand the regulatory processes driving RPE EMT, we surveyed TF-binding motifs associated with peaks that changed and that were associated with significantly changing genes ([Figure 4](#fig4){ref-type="fig"}B). For this analysis, we examined peaks with differential intensity (adjusted p value \< 0.1 and 2-fold change) between the RPE cobblestone and TNT conditions. For those peaks with a greater intensity in RPE cobblestone cells, we intersected the associated genes with the 1,413 genes that showed significantly *decreased* expression during EMT, resulting in 615 shared genes ([Figure 4](#fig4){ref-type="fig"}C, subset marked by ^∗^). For those peaks with a greater intensity in TNT-treated cells, we intersected the associated genes with the 1,426 genes that showed significantly *increased* expression during EMT, resulting in 625 shared genes ([Figure 4](#fig4){ref-type="fig"}C, subset marked by \$). For each case, we proceeded to uncover enriched TF consensus motifs in each subset by utilizing a motif analysis algorithm in the Homer suite of ChIP-seq tools ([@bib11]). Motif enrichment revealed a range of consensus sequences present within the RPE peak and EMT peak subsets (available at <http://neuralsci.org/computing>). In the RPE subset, 344 known motifs were enriched, and in the EMT subset, 324 known motifs were enriched (q \< 0.1). In both subsets the top ten motifs are against the same consensus sequences but in slightly different ranks. The Fra-1(bZip) motif is the top motif in both RPE and EMT peak subsets and it is promiscuous for the FOS family of TFs (*FOSL1*, *FOSL2*, *FOS*, and *FOSB*). We note that *FOSL1* exhibits a ∼17-fold increased transcription during TNT-induced EMT. We then constructed directed networks for both the RPE cells and TNT-induced EMT cells of the changing genes and their potential regulators identified by the motif analysis. We first assigned interactions between the potential regulatory TFs and those genes with specific consensus motifs in their enhancer peaks that changed expression with EMT. The approach is somewhat lenient, in that all potential interactions were assumed to occur and added to the networks. One caveat of our approach is that broader motifs, such as E box, general AP-1, and the Fra-1 motifs, were not included due to their lack of specificity to a single TF. Hence, *FOSL1* is not included in the constructed networks, even though our analysis described above indicates it could be functionally important.

After constructing the networks, they were visualized in Cytoscape (v.3.6.1) (complete networks at <http://neuralsci.org/computing>) and the minimum dominating set (MDS) and minimum connected dominating set (MCDS) were determined using the MDCS plug-in ([@bib26]). The MDS and MCDS are algorithms for determining the key nodes in a network, in this case, the key TFs regulating a gene network. MDS identifies the minimum subset of nodes (subset A) such that every node not in A is directly adjacent to a node in A; MCDS identifies a similar subset with the caveat that all nodes in A must also be directly connected to each other. To focus on potential key regulatory genes and interactions in each complete network, we created subgraphs containing only the TFs that have changing expression and enriched consensus motifs ([Figures 4](#fig4){ref-type="fig"}D and 4E).

The complete "Up in RPE" network ([Figure 4](#fig4){ref-type="fig"}D is the TF subgraph) has 614 nodes (genes) with 8,466 edges (connections). In this network, the MCDS factors are *KLF6*, *CRX*, *HIC1*, and *RUNX1*, and the MDS is *KLF3* and *OTX2*. We also created a subnetwork dropping TFs downregulated in RPE cobblestone cells as they undergo EMT, and in this case the MCDS factors are *BCL6*, *CRX*, *MITF*, *SOX9*, and *KLF9*, whereas the MDS factors are *CRX*, *SOX9*, and *KLF9*. *MITF* is a key TF in RPE development and function, and its inclusion as a central TF is expected, as is the case for *OTX2*, which directs the molecular network underlying RPE differentiation along with *MITF* ([@bib21]). *OTX2* expression drops by 26-fold in EMT RPE. The inclusion of *CRX* as a central factor in both the complete and subnetwork of Up in RPE is somewhat surprising given its well-established role in photoreceptor function and development, although it has been recognized more recently in RPE function in human and bovine retina ([@bib7]). *SOX9* is also important for RPE differentiation and in mature cells, *SOX9* regulates the key visual cycle genes ([@bib22]), explaining its significance in the Up in RPE network. It drops in expression by 6-fold in EMT RPE but retains prominence in the EMT network ([Figure 4](#fig4){ref-type="fig"}E), which is consistent with the known role that *SOX9* plays in the EMT of several cell types.

The complete "Up in EMT" network ([Figure 4](#fig4){ref-type="fig"}E is the TF subgraph) has 593 nodes and 8,890 edges and includes different central TFs. Examining this complete network, the MCDS factors are *KLF6*, *SOX17*, *GATA3*, *ETS1*, and *HIC1*, and the MDS factor is *KLF6*. In contrast to our findings on the Up in RPE network, the central TFs of the Up in EMT subnetwork (including only the TFs with increased expression in EMT) are not different from the complete network. Within both the Up in RPE and Up in EMT networks, KLF genes play a key role. Notably, *KLF6*, which increases in expression 2.6-fold after TNT treatment, is a central TF in both networks, and it has been demonstrated to have both repressor and activator activities. Antagonizing *KLF6* can inhibit TGF-β-induced EMT ([@bib17]). However, *KLF6* expression in kidney proximal tubule cells increased after EMT induction by TGF-β, and *KLF6* overexpression promoted an EMT-like phenotype ([@bib12]). These observations suggest a complex role for *KLF6* in EMT depending on tissue context or other transcriptional regulators.

NAM Promotes a Cobblestone Phenotype, Improves Expression of RPE Markers, and Inhibits EMT in RPESC-Derived RPE {#sec2.6}
---------------------------------------------------------------------------------------------------------------

Inhibition of TGF-β signaling can prevent loss of epithelial morphology ([@bib15], [@bib30], [@bib43]). Previously, we showed that NAM negatively regulates the TGF-β signaling pathway and several genes associated with TNF-α signaling in RPE ([@bib33]). In addition, NAM improves cobblestone phenotype in immortalized ARPE19 cells ([@bib10]). We found that, of the significantly changed genes in RPE treated with NAM, remarkably, 47% (226) were also significantly changed upon TNT treatment ([Table S4](#mmc){ref-type="supplementary-material"}B), and most (155) in the opposite direction ([Figures 5](#fig5){ref-type="fig"}A and 5B; [Table S4](#mmc){ref-type="supplementary-material"}C). The TF *FOSL1*, which binds the top enriched consensus sequence in both the cobblestone and TNT-induced RPE cells, falls into this latter category. Furthermore, many of the gene ontology categories associated with genes upregulated by TNT treatment and downregulated by NAM treatment are shared ([Figures 5](#fig5){ref-type="fig"}C and 5D; [Tables S4](#mmc){ref-type="supplementary-material"}D and S4E). Hence, we hypothesized that NAM may inhibit EMT and the TNT-induced changes in RPE.Figure 5Genes Changing Expression during TNT-Induced EMT versus Impact of NAM Treatment on Human RPE(A) RPE genes changing after NAM treatment and after TNT treatment.(B) Scatterplot of the 226 genes significantly changed in RPE cells common to both NAM and TNT treatments. x axis: log2 fold change after TNT treatment; y axis: log2 fold change after NAM treatment. Lower right and upper left quadrants (blue boxes) contain genes whose expression in TNT is opposed by NAM treatment.(C and D) Gene ontology enrichment analysis of gene categories aggregated based on semantic similarity using REVIGO and plotted as treemaps with top level descriptions, (C) genes upregulated during TNT-induced EMT, (D) genes from the lower right quadrant of (B). Comparison of the treemaps reveals similar strand enrichment for gene ontology categories related to blood vessel development, cell movement and adhesion, and apoptosis. Minor categories have been removed from treemap display to increase readability.

RPESC-RPE cultured without NAM had fibroblastic morphologies and appeared multilayered ([Figures 6](#fig6){ref-type="fig"}A and 6B, left panel), while those cultured with NAM were in a cobblestone monolayer ([Figure 6](#fig6){ref-type="fig"}B, right panel). The rate of change of transepithelial electrical resistance (TER) was compared between RPE cultured ± NAM and slope of regression was calculated. NAM increased the TER of RPESC-RPE (320 ± 32^.^cm^2^, p = 1.61 × 10^−45^ n = 9) compared with no NAM (1.36 ± 3.7, p = 0.73, n = 3) ([Figure 6](#fig6){ref-type="fig"}C). Tight junction-associated proteins ZO-1 and CLDN19 appropriately localized to the apical membranes at cell-cell contacts in RPE cells cultured with NAM but were undetectable in cultures without NAM ([Figure 6](#fig6){ref-type="fig"}D). NAM promoted expression of key RPE identity markers *MITF* (1.72 ± 0.18, p = 0.0021, n = 13), *OTX2* (1.33 ± 0.09, p = 0.0146 n = 6), and *RPE65* (13.09 ± 4.15, p = 0.0141 n = 12) ([Figure 6](#fig6){ref-type="fig"}E). Western blot analysis showed that RPE cells cultured with NAM express more E- than N-cadherin, consistent with EMT inhibition ([Figure 6](#fig6){ref-type="fig"}F). Next, we examined expression of several key EMT and PVR-related genes by qPCR, including *SNAI1*, *SNAI2*, and *ACTA2* (α-smooth muscle actin), which increases in expression during EMT as the cytoskeleton remodels. *COL1A1* encodes an extracellular matrix protein that is expressed in ERM tissue ([@bib1]) and increases 9.6-fold after TNT treatment ([Table S4](#mmc){ref-type="supplementary-material"}). NAM decreased expression of *SNAI1* (0.41 ± 0.05, p = 0.0001; n = 12), *SNAI2* (0.50 ± 0.05, p = 0.0001; n = 12), and *ACTA2* (0.07 ± 0.03, p = 0.0016; n = 3) ([Figure 6](#fig6){ref-type="fig"}G). Hence, NAM effectively inhibits RPE EMT.Figure 6NAM Protects RPESC-RPE Cells from Undergoing EMT(A) Schematic of RPESC-RPE culture procedure and analysis.(B) Phase images of adult human RPESC-RPE cultures without (CONTROL) and with NAM. Scale bars, 100 μm.(C) TER measurements of adult human RPE cultured without (CONT) and with NAM. N = 3 biological replicates.(D) Immunofluorescence images of ZO-1 and CLDN19 (red) after 1 month in culture with NAM (nuclear stain, DAPI, blue). Scale bars, 100 μm.(E) qPCR for RPE identity genes *MITF*, *OTX2*, and *RPE65*. N = 12 biological replicates.(F) Western blot analysis for E- and N-cadherin in three adult human RPE lines; vinculin as loading control.(G) qPCR analysis of EMT master regulator genes (*SNAI1* and *SNAI2*) and EMT marker (*ACTA2*).All values are relative to control without NAM (−). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; n = 3 biological replicates.

NAM Restores Epithelial Identity by Promoting Mesenchymal-to-Epithelial Transition and Prevents Human RPE from Transforming into ERM-like Membranes *In Vitro* {#sec2.7}
--------------------------------------------------------------------------------------------------------------------------------------------------------------

Importantly, we found that NAM can promote a mesenchymal-to-epithelial transition (MET) in RPE cells. RPE which had already undergone EMT were cultured for 30 days ± NAM ([Figure 7](#fig7){ref-type="fig"}A). NAM stimulated the reappearance of areas of cobblestone morphology ([Figure 7](#fig7){ref-type="fig"}B), increased expression of RPE identity genes, *MITF* (2.03 ± 0.18, p = 0.0054; n = 5) and *RPE65* (5.34 ± 1.43, p = 0.039; n = 5) ([Figure 7](#fig7){ref-type="fig"}C), and decreased expression of EMT-associated genes: *SNAI1* (0.33 ± 0.17, p = 0.0077; n = 5) and *SNAI2* (0.19 ± 0.03, p = 0.0036; n = 3) ([Figure 7](#fig7){ref-type="fig"}D). Furthermore, NAM treatment inhibited EMT stimulated by TNT ([Figures 7](#fig7){ref-type="fig"}E and 7F) ([Video S2](#mmc7){ref-type="supplementary-material"}) and qPCR analysis showed significantly reduced expression of EMT markers *SNAI1* (0.14 ± 0.03, p = 0.0002; n = 3) and *SNAI2* (0.12 ± 0.05, p = 0.0005; n = 3) ([Figure 7](#fig7){ref-type="fig"}G). To evaluate whether primary RPE may also form contractile membranes after TNT treatment, freshly isolated RPE cells were plated into TNT or TNT + NAM conditions. Given that, by single-cell analysis, primary RPE cells that are largely post-mitotic ([@bib34]), and the proliferative RPESCs are a minor subpopulation (\<10%), we predicted only a low level of mass formation that would be inhibited by NAM treatment, which is what we observed ([Figures 7](#fig7){ref-type="fig"}H and 7I). These data demonstrate that NAM can prevent TNT-induced contractility and partially reverse the EMT phenotype in adult human RPESC-RPE cells in a model of PVR.Figure 7NAM Promotes RPESC-RPE MET and Inhibits 3D ERM-like Membrane Formation(A) Schematic of experiment to determine if NAM can stimulate MET.(B) Phase images of RPE cultures showing NAM treatment restores cobblestone morphology, scale bars, 100 μm.(C and D) qPCR analysis for (C) RPE identity genes *MITF* and *RPE65*, and (D) EMT master genes *SNAI1* and *SNAI2*. N = 5 biological replicates.(E) Schematic of experiment to determine if NAM can prevent TNT-induced changes in adult RPESC-RPE cultures.(F) Phase images of cultured adult human RPE cells after 5 days of culture in CONTROL (Vehicle), TNT, or TNT + NAM. Scale bars, 100 μm.(G) qPCR analysis of EMT master genes *SNAI1* and *SNAI2*. N = 3 biological replicates.(H) Phase images of primary adult human RPE after 5 days in culture in CONTROL (Vehicle), TNT, or TNT + NAM. Scale bars, 100 μm.(I) Quantification of number of 3D masses produced primary RPE with vehicle control (pCON), primary RPE treated with TNT (pTNT), RPESC-RPE (sTNT), primary RPE treated with TNT + NAM (pTNT + NAM). N = 3 biological replicates.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Video S2. Video of RPE Treated with TGF-β1, TNF-α, and Nicotinamide

Discussion {#sec3}
==========

Human RPE cells undergo pathological changes, including EMT, leading to conditions that can significantly impair vision. Treatment with TNT is a strong inducer of several changes seen in ERM and PVR formation, including EMT and production of contractile membranes, and here we investigated the global transcriptomic and epigenomic changes associated with these dramatic changes in RPE cells. Furthermore, we found that the vitamin B3 derivative NAM inhibits RPE EMT and prevents the formation of contractile fibroblastic membranes that resemble the damaging ERMs found in macular pucker and PVR.

TNT treatment resulted in widespread changes in the RPE epigenome, with an unusual bias toward activation of regulatory elements, rather than decommissioning. These changes in active chromatin signatures occurred largely at distal enhancers, while promoters were less affected. This is consistent with enhancers serving as the primary mediators of RPE cell state change and being utilized in a highly dynamic manner. H3K27ac enrichment at enhancers shows a high degree of cell type specificity and responsiveness to signaling ([@bib5]); therefore, the changes we observe at putative enhancers are consistent with the RPE undergoing a drastic change in regulatory programs in response to these changes in the signaling environment.

Global epigenomic changes associated with EMT have been assessed in other cell types. In a mouse hepatocyte cell line treated with TGF-β treatment to stimulate EMT, a striking loss of heterochromatin was observed, with a global reduction in the heterochromatin mark H3K9Me2, an increase in H3K4Me3 and an increase in the transcriptional mark H3K36Me3 ([@bib23]). Immortalized human mammary epithelial cells stimulated to undergo EMT by overexpression of *TWIST1* showed an increase in H3K4me3 and dramatic reduction in the repressive mark H3K27me3, with loss at half of the gene promoters ([@bib20]). Human lung A549 alveolar epithelial cells treated with TGF-β to stimulate EMT, however, produced no overall detectable change in global H3K4me3 levels but exhibited a global loss of the active euchromatin mark H3K9ac and an increase in the repressive mark H3K27me3 ([@bib20]). These different observations may be attributable to different methodologies, the mode of EMT induction, time points of assessment, and to the specific cell types involved. We note again that, since enhancers are often characterized by high cell-type specificity, the specific regulatory enhancer elements utilized for their activation may be different in distinct epithelial cell types. Thus, it will be valuable to determine whether the massive reorganization of enhancer patterns we observed in RPE also accompanies EMT in other cell types and whether the activated enhancers are overlapping or distinct. Associations between EMT-associated TFs and epigenetic regulatory machinery provide plausible routes to alterations in DNA methylation and histone modifications ([@bib37]) that may have cell-specific outcomes and raise the importance of documenting these changes at molecular levels in diverse tissues and, where possible, with unified approaches to enable more precise comparisons.

Because TNT treatment elicited changes in over 40,000 identified epigenetic regions, we used global transcriptomics and differential gene expression analysis to reveal genes that exhibited concerted epigenetic and transcriptional changes. RNA-seq analysis identified genes that demonstrated expression changes between cobblestone and TNT conditions revealing associations with pathways known to be predominant in EMT. Acquisition of contractile properties is prominent after TNT treatment and represents the potentially damaging maturation of ERMs, so it is interesting that several genes associated with smooth muscle contraction, including *MYL9*, *MYL6*, the non-muscle myosin *MYH9*, and several tropomyosin genes, are significantly upregulated, and targeting these may reduce the impact of pulling and detaching retinal tissue.

Comparison of the significantly changing genes between cobblestone and TNT-treated RPE and association with putative active enhancers and promoters in our analysis revealed several TFs that are candidate regulators of RPE EMT. In addition to the canonical EMT factors, and those already described through a network analysis focused on ARPE19 cells ([@bib28]), several have not been explored in the context of RPE EMT and ERM development, such as *KLF6*, *SOX17*, and *FOSL1*. It will be worthwhile to examine whether such TFs highlighted by our network analyses are involved in the initiation of ERM production and contraction during progression of macular pucker and PVR. Our observations that NAM inhibits RPE EMT and moreover can initiate MET, opens opportunities to develop deeper insight into the processes involved, and a pathway to new therapeutic approaches for clinical conditions subsequent to RPE EMT, including ERM, macular pucker and PVR.

Experimental Procedures {#sec4}
=======================

Human Adult RPESC-RPE Culture {#sec4.1}
-----------------------------

Human whole globes and posterior shells (globes without anterior segments) from donors aged 36--90 years within 40 h of death were obtained from the National Disease Research Interchange, Philadelphia, PA, the Eye-Bank for Sight Restoration, New York, NY, the Lions Eye Bank, Albany, NY, and Miracle In Sight, Winston-Salem, NC. Eye dissection and culture protocols were as published ([@bib3], [@bib8]). RPE cells were isolated and plated on tissue culture plates coated with Synthemax II (Corning) in RPE medium with 10% fetal bovine serum (FBS) and 10 mM NAM and fed 3 times a week; after the first week, FBS was reduced to 2%.

Patient-Dissected ERM Specimens {#sec4.2}
-------------------------------

Specimens were obtained within 24 h of surgery at the New York Eye and Ear Infirmary (Mount Sinai Hospital, NY) and Capitol Region Retina (Albany, NY) and were immediately processed for RNA extraction and qPCR analysis. Statistical analysis was conducted using Student\'s t test. Studies were conducted under IRB oversight.

EMT Model {#sec4.3}
---------

Human RPESC-RPE cultures were treated with 0.25% trypsin for 5 min, washed and replated at 3 × 10^4^ cells per 1.9 mm^2^ in a 24-well plate in DMEM/F12 + 5% FBS, L-glutamine, Na-pyruvate, non-essential amino acid, penicillin/streptomycin. After 24 h, 10 ng/mL TGF-β1 or 10 ng/mL TNF-α, or 10 ng/mL of each (TNT) were added versus vehicle as control, and cultures were fed every other day for 5 days.

Immunohistochemistry and Western Blot {#sec4.4}
-------------------------------------

Adult human RPESC-RPE on 24-well size Transwell inserts (Corning) were fixed with 4% paraformaldehyde for 10 min, rinsed 3× with phosphate-buffered saline, permeabilized with 0.02% Tween 20, and blocked with normal goat or donkey serum (5%) in BSA (1%) for 1 h. Primary antibodies against SNAI1 (goat, diluted 1:100, R&D Systems, cat. no. AF3639), Z-O1 (mouse, diluted 1:100, Invitrogen, cat. no. 339100), and CLDN19 (rabbit, diluted 1:100, Abcam, cat. no. ab74374) were added, incubated overnight at 4°C, then washed and incubated for 45 min at room temperature with the corresponding Alexa Fluor-conjugated secondary antibodies (1:1,000) (Life Technologies Alexa Fluor 488 donkey anti-goat IgG \[(H + L\], cat. no. A11055; Alexa Fluor 488 goat anti-mouse IgG \[H + L\], cat. no. A11017; Life Technologies Alexa Fluor 488 donkey anti-rabbit IgG \[H + L\], cat. no. A11070). DAPI (Roche, cat. no. 10-236-276-001) was added at room temperature for 45 min as a nuclear counterstain. Cells on Transwell inserts were mounted on glass slides with Prolong Gold (Life Technologies, cat. no. P36930) and imaged by fluorescent microscopy (Leica DM5500). Western blot methods are provided in [Supplemental Information](#app2).

RNA Isolation and qPCR {#sec4.5}
----------------------

Adult human RPESC-RPE cells were incubated in RNAprotect Cell Reagent (QIAGEN, cat. no. 76,526), centrifuged at 10,000 rpm for 10 min, and the pellet resuspended in buffer RLT plus and RNA harvested according to the manufacturer\'s protocol (QIAGEN RNeasy Plus Mini Kit, cat. no. 74,136). Samples were passed through a gDNA eliminator column (QIAGEN). cDNA was made using the high-capacity RNA to cDNA conversion kit (Applied Biosystems, cat. no. 4387406). qPCR was performed using Radiant Green Lo-ROX qPCR Kit (Alkali, cat. no. QS1020) and Applied Biosystems ViiA7 Real-Time PCR System (Life Technologies). qPCR primers are provided in [Supplemental Information](#app2). Statistical analysis was conducted using Student\'s t test.

ChIP-Seq {#sec4.6}
--------

ChIP assays were performed from ∼10^7^ RPESC-RPE cells per experiment, across two different donors, according to ([@bib29]), with slight modification; further details in [Supplemental Information](#app2). Functional annotation of enhancers was obtained with GREAT (<http://great.stanford.edu/public/html/input.php>), using the Basal plus extension association rules and the whole human genome as background.

RNA-Seq {#sec4.7}
-------

RPESC-RPE cells from two different donors were treated with TGF-β1 TNF-α, TNT, or vehicle control as described above for 5 days. RNA was extracted with TRIzol (Invitrogen) following THE manufacturer\'s recommendations. Total RNA (10 μg) underwent two rounds of purification using Dynaloligo-dT beads (Invitrogen), was fragmented with 10× fragmentation buffer (Ambion), and used for first-strand cDNA synthesis using random hexamer primers (Invitrogen) and SuperScript II enzyme (Invitrogen). Double-strand cDNA was obtained by adding RNaseH (Invitrogen) and DNA Pol I (New England BioLabs) and used for Illumina library preparation and sequenced with the Illumina HiSeq.

Transepithelial Resistance Measurements {#sec4.8}
---------------------------------------

Transepithelial resistance (TER) of RPESC-RPE cells grown in Transwell inserts (Corning) ±10 mM NAM in RPE medium was measured weekly and within 2 min of removal from the incubator using an EVOM2 (World Precision Instruments) Epithelial Voltohmmeter. Statistical analysis was conducted using Student\'s t test.

Bioinformatic Analysis {#sec4.9}
----------------------

### ChiP-Seq {#sec4.9.1}

To identify the approximate positions of regulatory elements from histone modification ChIP-seq profiles alone, we calculated kernel density estimate tracks with bimodal kernels ([@bib4]) and identified peaks in the product of the combined H3K27 and H3K4 signals. To analyze changes in histone modifications, we calculated the read coverage for each sample over a combined set of detected peaks and performed a differential analysis with DESeq2.

### RNA-Seq {#sec4.9.2}

Fastq files were mapped using STAR aligner with the NCBI26/hg18 genome to generate bam files. Reads per genes were counted and read into R using the GenomicRanges package. Significantly changing genes were identified using the edgeR and DEseq2 packages. Gene ontology and KEGG enrichment analysis was performed with the goseq package.

Integration of ChIP-seq and RNA-seq data: was done in R and with Homer ChIP-seq toolset. For the network analysis, adjacency lists were generated in R and network visualization in Cytoscape 3.5. The MCDS and MDS analysis was done with the MCDS Cytoscape app. See [Supplemental Information](#app2) for R code and more details. REVIGO (<http://revigo.irb.hr/>) was used to generate treemaps for the gene ontology analysis.
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